MX2022011233A - Composiciones y metodos para enfermedades oculares relacionadas con la edad que comprenden altas concentraciones de vitaminas. - Google Patents

Composiciones y metodos para enfermedades oculares relacionadas con la edad que comprenden altas concentraciones de vitaminas.

Info

Publication number
MX2022011233A
MX2022011233A MX2022011233A MX2022011233A MX2022011233A MX 2022011233 A MX2022011233 A MX 2022011233A MX 2022011233 A MX2022011233 A MX 2022011233A MX 2022011233 A MX2022011233 A MX 2022011233A MX 2022011233 A MX2022011233 A MX 2022011233A
Authority
MX
Mexico
Prior art keywords
compositions
methods
vitamins
high concentrations
eye diseases
Prior art date
Application number
MX2022011233A
Other languages
English (en)
Inventor
Daniel J Stein
Melinda Divito
Lester Hosten
Original Assignee
Bausch Lomb Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch Lomb Ireland Ltd filed Critical Bausch Lomb Ireland Ltd
Publication of MX2022011233A publication Critical patent/MX2022011233A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción describe composiciones que comprenden un potente complejo de vitaminas B y sales farmacéuticamente aceptables de cualquiera de los anteriores. Las composiciones son útiles en métodos para tratar afecciones asociadas con una pérdida de agudeza visual que incluyen, por ejemplo, degeneración macular relacionada con la edad.
MX2022011233A 2020-03-11 2021-03-10 Composiciones y metodos para enfermedades oculares relacionadas con la edad que comprenden altas concentraciones de vitaminas. MX2022011233A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062988375P 2020-03-11 2020-03-11
US202063045585P 2020-06-29 2020-06-29
PCT/IB2021/052005 WO2021181309A1 (en) 2020-03-11 2021-03-10 Compositions and methods for age related eye diseases comprising high concentrations of vitamins

Publications (1)

Publication Number Publication Date
MX2022011233A true MX2022011233A (es) 2022-12-13

Family

ID=74874915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011233A MX2022011233A (es) 2020-03-11 2021-03-10 Composiciones y metodos para enfermedades oculares relacionadas con la edad que comprenden altas concentraciones de vitaminas.

Country Status (10)

Country Link
US (1) US20230117576A1 (es)
EP (1) EP4117649A1 (es)
JP (1) JP2023533632A (es)
KR (1) KR20220152231A (es)
CN (1) CN115515574A (es)
AU (1) AU2021233236A1 (es)
BR (1) BR112022018109A2 (es)
CA (1) CA3175093A1 (es)
MX (1) MX2022011233A (es)
WO (1) WO2021181309A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6953588B2 (en) * 2002-10-25 2005-10-11 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US20080063730A9 (en) * 2004-07-29 2008-03-13 Giordano John A Methods for prophylactic and therapeutic nutritional supplementation
US20060134226A1 (en) * 2004-11-16 2006-06-22 Todd Leonard Compositions useful to treat ocular neovascular diseases and macular degeneration
JP2010538674A (ja) * 2007-09-19 2010-12-16 オフサルモファーマ・アクチェンゲゼルシャフト 栄養補助剤およびそのような補助剤を含む強化食品
US20110142766A1 (en) * 2009-12-16 2011-06-16 Sal Rafanelli Effervescent Multi-Vitamin Formulation and Methods of Use Thereof
TW201406382A (zh) * 2012-08-09 2014-02-16 Tci Co Ltd 具視網膜保護功能之複方組成物及應用
CN103340891A (zh) * 2013-06-08 2013-10-09 哈尔滨珍宝制药有限公司 一种含b族维生素的组合物及其制备方法
CN108606199A (zh) * 2018-03-27 2018-10-02 佛山市体视能饮料有限公司 一种可缓解体力和视力疲劳的功能性饮料及其制备方法

Also Published As

Publication number Publication date
EP4117649A1 (en) 2023-01-18
AU2021233236A1 (en) 2022-09-15
CN115515574A (zh) 2022-12-23
WO2021181309A1 (en) 2021-09-16
BR112022018109A2 (pt) 2022-11-08
KR20220152231A (ko) 2022-11-15
US20230117576A1 (en) 2023-04-20
CA3175093A1 (en) 2021-09-16
JP2023533632A (ja) 2023-08-04

Similar Documents

Publication Publication Date Title
WO2007046083A3 (en) Compositions for treatment of eye diseases
MX2018014868A (es) Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
MX2021006092A (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
TN2009000241A1 (en) Nutritional supplement composition for treatment of ocular diseases
AU2018218696B2 (en) Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid
Sandberg et al. Lack of scientific rationale for use of valproic acid for retinitis pigmentosa
MX2022005063A (es) Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.
MX2022001062A (es) Peptidos para el tratamiento de degeneracion macular no exudativa y otros trastornos del ojo.
TN2019000112A1 (en) Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma
MX2022011235A (es) Composiciones y metodos para la salud ocular que comprenden areds y complejo de vitamina b.
MX2022011233A (es) Composiciones y metodos para enfermedades oculares relacionadas con la edad que comprenden altas concentraciones de vitaminas.
NZ757557A (en) Methods of preventing or treating ophthalmic diseases
AU2018240462A1 (en) Drugs and compositions for the treatment of ocular disorders
WO2008048675A3 (en) Treatment for age-related macular degeneration and other diseases of the eye
MX2022000928A (es) Proceso para la preparacion de suspensiones acuosas oftalmicas esteriles de nanocristales de la forma a de propionato de fluticasona.
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
MX2021014000A (es) Formulaciones oftalmicas topicas de liposomas cargados con acetonido de triamcinolona para la prevencion del engrosamiento macular y sus resultados visuales asociados despues de la cirugia del cristalino.
MX2022011234A (es) Composiciones y métodos para la salud ocular que comprenden ácidos grasos de cadena muy larga.
WO2019090010A3 (en) Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
MX2023006902A (es) Uso de activadores de sgc para el tratamiento de enfermedades oftalmologicas.
CN105456239A (zh) 一种虾青素和叶黄素组合物及其用途
Beatty et al. Visual outcome after antioxidant supplementation
MX2020011535A (es) Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.
MX2019013192A (es) Método de tratamiento y diseño de ensayo clínico para la atrofia geográfica debida a la degeneración macular relacionada con la edad.
Makino et al. Surgical outcomes of sensory strabismus